Reviva Pharmaceuticals Holdings: Positive Phase 3 Data and Favorable Safety Profile Support Buy Rating

Reviva Pharmaceuticals Holdings (RVPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding Reviva Pharmaceuticals Holdings’ recent developments. The company announced positive 12-month data from their Phase 3 open-label extension study of brilaroxazine, which demonstrated sustained efficacy across key symptom domains in schizophrenia, such as positive, negative, cognitive, and agitation symptoms. This data underscores brilaroxazine’s potential as a long-term treatment option.
Additionally, the safety profile of brilaroxazine is favorable, with a 35% discontinuation rate that is significantly lower than the typical 60%-70% seen in similar trials for other antipsychotics. Importantly, brilaroxazine was not associated with common adverse effects like prolactin elevation, which can lead to sexual dysfunction. The accumulating data from these trials is seen as reducing the risk for the upcoming second Phase 3 trial, which is expected to proceed more swiftly due to a less competitive trial landscape. These factors collectively support the Buy rating for Reviva Pharmaceuticals Holdings.

In another report released on May 23, Benchmark Co. also maintained a Buy rating on the stock with a $14.00 price target.

RVPH’s price has also changed moderately for the past six months – from $1.200 to $0.880, which is a -26.67% drop .